- Home
- MMV vs PMCB Comparison
MMV vs PMCB Comparison
Compare MMV & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMV
- PMCB
- Stock Information
- Founded
- MMV 2015
- PMCB 1996
- Country
- MMV China
- PMCB United States
- Employees
- MMV N/A
- PMCB N/A
- Industry
- MMV Blank Checks
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MMV Finance
- PMCB Health Care
- Exchange
- MMV Nasdaq
- PMCB Nasdaq
- Market Cap
- MMV 14.1M
- PMCB 13.9M
- IPO Year
- MMV N/A
- PMCB N/A
- Fundamental
- Price
- MMV $0.37
- PMCB $1.75
- Analyst Decision
- MMV
- PMCB
- Analyst Count
- MMV 0
- PMCB 0
- Target Price
- MMV N/A
- PMCB N/A
- AVG Volume (30 Days)
- MMV 847.4K
- PMCB 56.4K
- Earning Date
- MMV 01-01-0001
- PMCB 12-13-2024
- Dividend Yield
- MMV N/A
- PMCB N/A
- EPS Growth
- MMV N/A
- PMCB N/A
- EPS
- MMV N/A
- PMCB 0.54
- Revenue
- MMV $9,008,244.00
- PMCB N/A
- Revenue This Year
- MMV N/A
- PMCB N/A
- Revenue Next Year
- MMV N/A
- PMCB N/A
- P/E Ratio
- MMV N/A
- PMCB $3.21
- Revenue Growth
- MMV N/A
- PMCB N/A
- 52 Week Low
- MMV $0.32
- PMCB $1.39
- 52 Week High
- MMV $2.05
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- MMV 44.92
- PMCB 49.02
- Support Level
- MMV $0.34
- PMCB $1.57
- Resistance Level
- MMV $0.41
- PMCB $1.92
- Average True Range (ATR)
- MMV 0.04
- PMCB 0.16
- MACD
- MMV 0.00
- PMCB -0.01
- Stochastic Oscillator
- MMV 38.54
- PMCB 50.00
About MMV MultiMetaVerse Holdings Limited
MultiMetaVerse Holdings Ltd is an animation and entertainment company. It is devoted to establishing an open community for its global users comprised of animation viewers, game players, and content creators and to providing high-quality and immersive entertainment experiences by way of original content, user-generated content, and professional user-generated content.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.